Glaukos Corp. Files 2023 Annual Report on Form 10-K

Ticker: GKOS · Form: 10-K · Filed: Feb 23, 2024 · CIK: 1192448

Sentiment: neutral

Topics: 10-K, Glaukos Corp, Annual Report, Medical Devices, Financials

TL;DR

<b>Glaukos Corp. has filed its 2023 annual report (10-K) detailing its fiscal year performance and financial standing.</b>

AI Summary

GLAUKOS Corp (GKOS) filed a Annual Report (10-K) with the SEC on February 23, 2024. Glaukos Corp. filed its 2023 Form 10-K on February 23, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is 1 Glaukos Way, Aliso Viejo, CA 92656. The company's phone number is 949-367-9600. Glaukos Corp. is incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking GLAUKOS Corp, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Glaukos Corp.'s financial health, operational performance, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's progress and future prospects. The detailed financial statements and risk factors within the 10-K are essential for stakeholders to understand the company's market position, potential challenges, and compliance with regulatory requirements.

Risk Assessment

Risk Level: medium — GLAUKOS Corp shows moderate risk based on this filing. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing potential risks to its market position and profitability.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to assess Glaukos Corp.'s performance and identify potential investment opportunities or risks.

Key Numbers

Key Players & Entities

FAQ

When did GLAUKOS Corp file this 10-K?

GLAUKOS Corp filed this Annual Report (10-K) with the SEC on February 23, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by GLAUKOS Corp (GKOS).

Where can I read the original 10-K filing from GLAUKOS Corp?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by GLAUKOS Corp.

What are the key takeaways from GLAUKOS Corp's 10-K?

GLAUKOS Corp filed this 10-K on February 23, 2024. Key takeaways: Glaukos Corp. filed its 2023 Form 10-K on February 23, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal business address is 1 Glaukos Way, Aliso Viejo, CA 92656..

Is GLAUKOS Corp a risky investment based on this filing?

Based on this 10-K, GLAUKOS Corp presents a moderate-risk profile. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing potential risks to its market position and profitability.

What should investors do after reading GLAUKOS Corp's 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to assess Glaukos Corp.'s performance and identify potential investment opportunities or risks. The overall sentiment from this filing is neutral.

How does GLAUKOS Corp compare to its industry peers?

Glaukos Corp. operates in the medical device industry, specifically focusing on ophthalmic surgical products and drug delivery systems.

Are there regulatory concerns for GLAUKOS Corp?

The company is subject to the regulations of the U.S. Securities and Exchange Commission (SEC) for its public filings, including the annual 10-K report.

Industry Context

Glaukos Corp. operates in the medical device industry, specifically focusing on ophthalmic surgical products and drug delivery systems.

Regulatory Implications

The company is subject to the regulations of the U.S. Securities and Exchange Commission (SEC) for its public filings, including the annual 10-K report.

What Investors Should Do

  1. Review the full 10-K filing for detailed financial statements and management discussion.
  2. Analyze the risk factors section to understand potential challenges and uncertainties.
  3. Compare the 2023 performance metrics with previous years to identify trends.

Key Dates

Year-Over-Year Comparison

This is the initial filing of the 2023 Form 10-K, providing the first comprehensive look at the company's performance for the fiscal year ending December 31, 2023.

Filing Stats: 4,480 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-02-23 17:23:59

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 40 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 53 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data. 54 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 91 Item 9A.

Controls and Procedures

Controls and Procedures. 92 Item 9B. Other Information. 94 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 94 PART III Item 10. Directors, Executive Officers and Corporate Governance. 95 Item 11.

Executive Compensation

Executive Compensation. 95 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 95 Item 13. Certain Relationships and Related Transactions, and Director Independence. 95 Item 14. Principal Accountant Fees and Services. 95 PART IV Item 15. E xhibits and Financial Statement Schedules. 96 Item 16. Form 10-K Summary 99 We use Glaukos , our logo, iStent , iStent inject W , iStent infinite , iPrism , iDose TR , iPRIME , MIGS, Avedro , Photrexa , iLink , KXL , Epioxa, iLution, Retina XR and other marks as trademarks. This report contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report, including logos, artwork and other visual displays, may appear without the or symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. References throughout this document to the "Company," "we," "us," "our," or "Glaukos" refer to Glaukos Corporation and its consolidated subsidiaries. Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical or current facts in this report or referred to or incorporated by reference into this report are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "co

BUSINESS

ITEM 1. BUSINESS Overview Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device commercially in 2012. We also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus, that was approved by the United States (U.S.) Food and Drug Administration (FDA) in 2016. We are developing a portfolio of platforms to support ongoing pharmaceutical and medical device innovations. Products and product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders such as keratoconus, dry eye and refractive vision correction, and retinal diseases such as neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Ophthalmic diseases and disorders are a national and global health concern and, as the population ages, the number of individuals with vision impairment and blindness is increasing. Moreover, improving access to cost-effective tools is increasing the diagnosis of sight-threatening ocular diseases globally and driving demand for innovative products, technologies, and therapies that improve clinical outcomes, demonstrate favorable safety profiles and provide ease of use and reliability. In response to the significant unmet needs that exist within ophthalmology we have designed commercial and development-stage solutions to provide ophthalmologists and other eye care professionals with various treatment options. Our commercial solutions and development-stage product candidates include: MIGS products that primarily invol

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing